India: Patent Newsletter January 2015

Last Updated: 3 February 2015
Article by Lall & Sethi Advocates

The story continues......... those who have been reading our past newsletters will understand that in the patent landscape our focus has been pharmaceuticals. This is not intentional and we do try very hard to veer away from it and focus on other technology areas as well, but since so much activity is always happening in this area, we are compelled to write and focus about this technology area. Here we are again! Back with another edition with some more news in the pharmaceutical landscape. This time however it is notjust news, we have tried to collect, collate and analyze data on enforcement of pharma patents in India in recent years. Specifically we are bringing you the trend in the relief granted to plaintiffs in these disputes.

And it is that time of the year again! The deadline for filing working statements for granted patents is just round the corner. We bring you an updated article on the working of patents in India with the latest case law in this regard.

A few words patting the Patent Office on its back for bringing some muchneeded transparency and efficiency in its working will complete this edition.

We wish all our readers a wonderful 2015. We hope you find the information useful.

Right to Infringe?

This is the impression the world has of India in the pharmaceutical space. To the world India is a no-holdsbarred country where anyone (read the generic companies) can copy your invention and live-happily-everafter. However the reality may be quite different. With the Indian pharmaceutical market growing at double digit rates1 competition between the innovator companies and the generic companies is predictably fierce. As the innovators and the generics fight it out, we try and bring you a realistic picture from the Ground Zero!

Patentee's Rights and Protection

The rights of the patentee2 are enshrined in the Indian Patents Act, 1970 that gives the exclusive right to the patentee to prevent others, without his consent, from the act of making, using, offering for sale, selling or importing the patented product in India. In case of a process it is the exclusive right to prevent others, without his consent, from using that process and from using, offering for sale, selling or importing for those purposes the product obtained directly by that process in India. The rights are however subject to conditions stated in section 473. Infringement per se is not defined in the Act but flouting of these rights by a third person amounts to infringement.

The patentee can file a suit for infringement against the infringer. The Court can grant relief4 to the patentee in the form of an injunction and either damages or an account of profits. The Court can also order seizure of infringing goods.

The injunction granted by the Court can be either temporary or permanent. For granting interim injunctions the Courts follow three criteria5 to determine its grant: availability of a prima facie case (that a patent is valid), the balance of convenience and irreparable injury. Traditionally Courts have not been very keen on granting injunctions, either interim or permanent, in patent cases, especially in pharmaceutical disputes. Recently, however this scenario seems to be shifting.

What follows below is the trend in grant of injunctions in the pharmaceutical space in recent years for the protection of various drug molecules. Sitagliptin Merck Sharp and Dohme (MSD) found infringement of its patent covering the molecule Sitagliptin, an antihyperglycemic drug of the DipeptidylPeptidase-4 (DRP-4) inhibitor class for which theyfiled infringement suits against several parties.

The Court granted interim ex-parte injunction against eight defendants, while refused injunction against Glenmark. In case of infringement suit against Glenmark6, the Court held that since the plaintiff (MSD) had failed to prove that Sitagliptin Phosphate was identical in its properties to Sitagliptin, hence the product (Sitagliptin Phosphate) of the defendant (Glenmark) would be outside the purview of the plaintiff's patent. The Court averred that the plaintiff had not submitted any pleadings with regards to the fact that that Sitagliptin Phosphate was merely a new form of Sitagliptin, and did not result in the enhancement of its efficacy and was a mere combination of other derivatives of Sitagliptin. The fact that the plaintiff had obtained patents on Sitagliptin Phosphate in the US and Europe by showing that it was a new product worked against them. The patent application for Sitagliptin Phosphate had been earlier rejected by the Indian Patent Office. The matter had been referred for mediation, however since attempts to settle disputes have failed, matter is into the trial phase.


Roche filed several infringement suits between 2008 and 2010 against a number of generic drug companies namely Cipla, NatcoPharma, Dr. Reddy's, Glenmark, Oncare Life Sciences, Aureate Healthcare, Innova Life Sciences, Mylan Laboratories Inc, Fresenius Kabi, Accura Care Pharmaceuticals and Intas Pharma for its patent on a drug molecule "Human Epidermal Growth Factor Type- I/Epidermal Growth Factor Receptor (HER/EGFR)" inhibitor which is known as 'Erlotinib' for treatment of cancer. However, in nine of the ten cases the Court decided only on jurisdiction part and main issue of injunctive relief remains open. Only in Cipla's case Court rendered its decision7, denying permanent injunction to Roche. In this case Roche was denied permanent injunction based on the Court view that Cipla did not infringe on the patent, though patent was held valid by the Court. Appeals were filed by both the parties against the Court decision.The defendant also filed revocation application for the same patent before Intellectual Property Appellate Board. Later in the case, the two parties agreed to work with the Court direction to provide mediation. The mediation also has however failed, and the both the parties are back in the Court.


The patent covering the famous drug of Bayer used for treating kidney, liver and radioactive iodine resistant advanced thyroid cancers was the subject of the first Compulsory License granted to NatcoPharma Ltd. In December 2014 Supreme Court rejected Bayer's Special Leave Petition (SLP application) that challenged a July, 2014 order of the Bombay High Court that upheld the grant of the Compulsory License to produce a cheaper version of its patented drug Sorafenib8.

Bayer had filed infringement suit against Cipla in 2010 for the infringement of its patented drug Sorafenib.The Delhi High Court did not grant interim injunction to Plaintiff in 2010 suit which is still pending with the Court.


Bristol-Myers Squibb's (BMS) patent covering the drug molecule Dasatinib survived the Compulsory License grant by the Patent Office in 2013. Dastanib is a multi-BCR/Abl and Src family tyrosine kinase inhibitor for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome – positive acute lymphoblastic leukemia (Ph+ ALL).

Earlier BMS had filed infringement suits against several parties for infringing its patent covering the drug molecule Dasatinib. It managed to get interim injunctions against Dr. BPS Reddy, Hetero Drugs, BDR Pharmaceuticals and Natco to restrain them from infringing its patent. Delhi High Court however refused granting an interim injunction against Shilpa Medicare for the same drug.


Novartis filed several suits of infringement against parties infringing its drug molecule Vildagliptin, an antihyperglycemic agent of the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class of drugs.

In seven separate suits for infringement filed by Novartis in the Delhi High Court in 2014 against the various Indian Generic companies like Ranbaxy Laboratories, Wockhardt Ltd, Biocon, Alembic Pharmaceuticals, Glenmark Generics, Cadila Healthcare and Bajaj Healthcare, quia timet ex-parte interim injunctions were granted to Novartis. The Court granted permanent injunction to Novartis against Bajaj Healthcare.


Bristol-Myers Squibb (BMS) was denied an interim injunction by Hyderabad Trial Court in a suit against generic manufacturer Matrix (owned by Mylan) regarding the export of HIV Drug Atazanavir to Venezuela. While BMS had no product patents in either India or Venezuela, they had brought the suit on the basis of two secondary process patents.

The plaintiff appealed in the Hyderabad High Court against the trial Court decision that was rejected and thereby denying the interim injunction application, noting that the applicants failed to demonstrate a prima facie case and balance of convenience in its favour.

Glatiramer Acetate:

Teva Pharmaceutical Industries Ltd (Teva) was denied interim injunction against Natco Pharma Ltd by the Delhi High Court in an infringement suit for infringement of two patents covering the process of making Glatiramer Acetate for want of appropriate jurisdiction. Glatiramer Acetate is an immunomodulator drug used to treat multiple sclerosis. Natco is manufacturing Glatiramer Acetate in India on behalf of Mylan for sale outside India. The Court refused the application on the basis of Delhi High Court not being the correct jurisdiction as the patents in question were process patents and not product patents.


Astra Zeneca AB sued Glenmark Generics Ltd for infringing its patent on its anti-diabetic drug Saxagliptin monohydrate which is co-developed by Bristol Myers Squibb. The plaintiff alleged that Glenmark exported the Saxagliptin. The Delhi High Court has passed a status quo order that allows Glenmark to continue export of Saxagliptin Monohydrate only.


Symed Laboratories Pvt. Ltd. (Symed) filed suits of infringement against several parties for infringement of its patents covering Linezolid intermediates and process for the perpetration of Linezolid and related compounds. Linezolid is a synthetic antibiotic.

The court granted ex-parte injunctions against Sharon Bio- Medicine and Optimus Pharma and permanent injunction against Alken Laboratories.

Imatinib Mesylate:

Novartis AG sued several generic manufacturers over the strength of its EMR (Exclusive Marketing Right) obtained for its drug, the beta crystalline form of Imatinib Mesylate in the Madras High Court. The Court issued an ex-parte injunction against six generic manufactures (which includes Cipla, Ranbaxy, SunPharma, Emcure, Hetero Drugs, Intas) preventing them from producing the drug. However, in another parallel litigation, the Bombay High Court refused to grant injunction against Meher Pharma, while ex-parte injunction granted in favour of plaintiff in Adarsh Pharma case.


Bristol - Myers Squibb filed a suit for infringement of its patent covering Entecavir, an antiviral drug used in the treatment of Hepatitis B virus (HBV) infection.The plaintiff prayed for permanent injunction to restrain Ranbaxy Laboratories from infringing its patent at Delhi High Court but injunction was not granted by the Court.


Pfizer and Sugen were granted an injunction preventing Cipla from launching Sunitinib that flouted their patent for the drug molecule by the Delhi High Court. Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of Renal Cell Carcinoma (RCC) and Gastrointestinal Stromal Tumor (GIST). Injunction was also granted against Natco and two other defendants.


Novartis filed a suit for permanent injunction against Cipla Ltd and got restraining orders against Cipla for infringing its patent covering its drug molecule Indacaterol, an ultra long-acting Beta 2- agonist approved for the treatment of Chronic Obstructive Pulmonary Disease (COPD).


Vifor (International) AG obtained ex-parte interim injunction against Symed Laboratories for violation of its patent which is related to process for preparation of water soluble iron carbohydrate complex of a particular weight. In Cadila vs Instacare Laboratories related to patent for process for amoxicillin formulation, the Ahmedabad High Court vacated the Trial Court's order of rejecting ex-parte ad-interim injunction to Cadila.

In K Ramu vs. AdayarAnandaBhavan and Muthulakshmi Bhavanthe Madras High Court granted interlocutory injunction for its patent which is related to low glycemic sweets.



2 Rights of patentees.—Subject to the other provisions contained in this Act and the conditions specified in section 47, a patent granted under this Act shall confer upon the patentee—

(a) where the subject matter of the patent is a product, the exclusive right to prevent third parties, who do not have his consent, from the act of making, using, offering for sale, selling or importing for those purposes that product in India;

(b) where the subject matter of the patent is a process, the exclusive right to prevent third parties, who do not have his consent, from the act of using that process, and from the act of using, offering for sale, selling or importing for those purposes the product obtained directly by that process in India.

3 Grant of patents to be subject to certain conditions.—The grant of a patent under this Act shall be subject to the condition that—

(1) any machine, apparatus or other article in respect of which the patent is granted or any article made by using a process in respect of which the patent is granted, may be imported or made by or on behalf of the Government for the purpose merely of its own use;

(2) any process in respect of which the patent is granted may be used by or on behalf of the Government for the purpose merely of its own use;

(3) any machine, apparatus or other article in respect of which the patent is granted or any article made by the use of the process in respect of which the patent is granted, may be made or used, and any process in respect of which the patent is granted may be used, by any person, for the purpose merely of experiment or research including the imparting of instructions to pupils; and

(4) in the case of a patent in respect of any medicine or drug, the medicine or drug may be imported by the Government for the purpose merely of its own use or for distribution in any dispensary, hospital or other medical institution maintained by or on behalf of the Government or any other dispensary, hospital or other medical institution which the Central Government may, having regard to the public service such dispensary, hospital or medical institution renders, specify in this behalf by notification in the Official Gazette.

4 Reliefs in suit for infringement.—(1) The reliefs which a court may grant in any suit for infringement include an injunction (subject to such terms, if any, as the court thinks fit) and, at the option of the plaintiff, either damages or an account of profits.

(2) The court may also order that the goods which are found to be infringing and materials and implements, the predominant use of which is in the creation of infringing goods shall be seized, forfeited or destroyed, as the court deems fit under the circumstances of the case without payment of any compensation.

5 The Supreme Court of India has provided precedential jurisprudence in SeemaArshadZaheer Case (SeemaArshadZaheer -vs- Municipal Corpn. of Greater Mumbai, (2006) 5 SCC 282) where the Court has laid down its guidelines for the grant of temporary injunction orders. The Court opined that "The discretion of the court is exercised to grant a temporary injunction only when the following requirements are made out by the plaintiff: (i) existence of a prima facie case as pleaded, necessitating protection of plaintiff's rights by issue of a temporary injunction; (ii) when the need for protection of plaintiff's rights is compared with or weighed against

the need for protection of defendant's rights or likely infringement of defendant's rights, the balance of convenience tilting in favour of plaintiff; and (iii) clear possibility of irreparable injury being caused to plaintiff if the temporary injunction is not granted. In addition, temporary injunction being an equitable relief, the discretion to grant such relief will be exercised only when the plaintiff's conduct is free from blame and he approaches the court with clean hands".

6 CS(OS) 586/2013, High Court of Delhi

7 CS(OS) No. 89/2008, CC 52/2008 & CM No.6436/2013 in RFA(OS) 92/2012 in High Court of Delhi

8 SC 30145/2014

Dowload article in full here.

p>The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.